COX-2 inhibitor

0 marketed 1 in Phase 3 1 in Phase 2

This page covers all COX-2 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting COX-2.

Targets

Phase 3 pipeline (1)

MK0663, etoricoxib · Organon and Co · Rheumatology
Etoricoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2, reducing prostaglandin synthesis and inflammation.

Phase 2 pipeline (1)

Celecoxib, COX-2 inhibitor; oral · Pfizer · Osteoarthritis, Rheumatoid Arthritis, Pain
Celecoxib selectively inhibits COX-2, an enzyme involved in inflammation and pain.